Alzheimer's disease is the most common form of dementia, characterized by two pathological hallmarks: amyloid-b plaques and neurofibrillary tangles 1 . The amyloid hypothesis of Alzheimer's disease posits that the excessive accumulation of amyloid-b peptide leads to neurofibrillary tangles composed of aggregated hyperphosphorylated tau 2,3 . However, to date, no single disease model has serially linked these two pathological events using human neuronal cells. Mouse models with familial Alzheimer's disease (FAD) mutations exhibit amyloid-b-induced synaptic and memory deficits but they do not fully recapitulate other key pathological events of Alzheimer's disease, including distinct neurofibrillary tangle pathology 4,5 . Human neurons derived from Alzheimer's disease patients have shown elevated levels of toxic amyloid-b species and phosphorylated tau but did not demonstrate amyloid-b plaques or neurofibrillary tangles [6][7][8][9][10][11] . Here we report that FAD mutations in b-amyloid precursor protein and presenilin 1 are able to induce robust extracellular deposition of amyloid-b, including amyloid-b plaques, in a human neural stem-cell-derived three-dimensional (3D) culture system. More importantly, the 3D-differentiated neuronal cells expressing FAD mutations exhibited high levels of detergent-resistant, silver-positive aggregates of phosphorylated tau in the soma and neurites, as well as filamentous tau, as detected by immunoelectron microscopy. Inhibition of amyloidb generation with b-or c-secretase inhibitors not only decreased amyloid-b pathology, but also attenuated tauopathy. We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-b-mediated tau phosphorylation. We have successfully recapitulated amyloid-b and tau pathology in a single 3D human neural cell culture system. Our unique strategy for recapitulating Alzheimer's disease pathology in a 3D neural cell culture model should also serve to facilitate the development of more precise human neural cell models of other neurodegenerative disorders.
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. The amyloid hypothesis of Alzheimer's disease posits that the excessive accumulation of amyloid-b peptide leads to neurofibrillary tangles composed of aggregated hyperphosphorylated tau 2, 3 . However, to date, no single disease model has serially linked these two pathological events using human neuronal cells. Mouse models with familial Alzheimer's disease (FAD) mutations exhibit amyloid-b-induced synaptic and memory deficits but they do not fully recapitulate other key pathological events of Alzheimer's disease, including distinct neurofibrillary tangle pathology 4, 5 . Human neurons derived from Alzheimer's disease patients have shown elevated levels of toxic amyloid-b species and phosphorylated tau but did not demonstrate amyloid-b plaques or neurofibrillary tangles [6] [7] [8] [9] [10] [11] . Here we report that FAD mutations in b-amyloid precursor protein and presenilin 1 are able to induce robust extracellular deposition of amyloid-b, including amyloid-b plaques, in a human neural stem-cell-derived three-dimensional (3D) culture system. More importantly, the 3D-differentiated neuronal cells expressing FAD mutations exhibited high levels of detergent-resistant, silver-positive aggregates of phosphorylated tau in the soma and neurites, as well as filamentous tau, as detected by immunoelectron microscopy. Inhibition of amyloidb generation with b-or c-secretase inhibitors not only decreased amyloid-b pathology, but also attenuated tauopathy. We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-b-mediated tau phosphorylation. We have successfully recapitulated amyloid-b and tau pathology in a single 3D human neural cell culture system. Our unique strategy for recapitulating Alzheimer's disease pathology in a 3D neural cell culture model should also serve to facilitate the development of more precise human neural cell models of other neurodegenerative disorders.
To develop human neural progenitor cells (hNPCs) that produce high levels of toxic amyloid-b species, we overexpressed human b-amyloid precursor protein (APP) or APP and presenilin 1 (PSEN1), containing FAD mutations. We first generated polycistronic lentiviral constructs designed to express human APP with both K670N/M671L (Swedish) and V717I (London) FAD mutations (APPSL) or APPSL and PSEN1 with DE9 FAD mutation (PSEN1(DE9)) (Fig. 1a) . These FAD lentiviral constructs were transfected into ReNcell VM human neural stem (ReN) cells (Millipore) . The transfected cells with GFP (ReN-G), mCherry (ReN-m), APPSL-GFP (ReN-GA), APPSL-GFP/PSEN1(DE9)-mCherry (ReNmGAP), APPSL-PSEN1(DE9)-mCherry (ReN-mAP) or GFP/APPSL-PSEN1(DE9)-mCherry (HReN-mGAP) were enriched on the basis of GFP and/or mCherry signals using fluorescence-activated cell sorting (FACS) (Extended Data Fig. 1a As previously reported [12] [13] [14] , most ReN cells differentiated into neuronal and glial cells within 3 weeks (Extended Data Figs 1d and 2a) . Immunofluorescence staining confirmed punctate localization of VGluT1 (vesicular glutamate transporter 1), a presynaptic marker, along with dendritic processes (Extended Data Fig. 2b ). Quantitative real-time PCR (qPCR) array analysis showed robust increases of neuronal and glial marker genes (Extended Data Fig. 2c ). Reverse-transcription-PCR (RT-PCR) analysis also showed a dramatic increase of 4-repeat adult tau isoforms following differentiation (Extended Data showing lentiviral internal ribosome entry sites (IRES) constructs. CMV, cytomegalovirus. b, Increased Ab 40 and Ab 42 levels in 6-week differentiated FAD ReN cells. Amyloid-b levels in conditioned media were normalized to total protein levels. *P , 0.05; **P , 0.01; ***P , 0.001; ANOVA followed by a post hoc Dunnett's test; n 5 3 per each sample. c, Amyloid-b levels are dramatically decreased in FAD ReN cells after treatment with 1 mM b-secretase inhibitor IV or 3.7 nM compound E. Mean 6 s.e.m.; *P , 0.05; **P , 0.01; ***P , 0.001; ANOVA followed by a post hoc Dunnett's test; n 5 3 per each sample; ND, not detected. exhibit voltage-gated potassium and sodium currents after 29 days of differentiation (Extended Data Fig. 2e-h ), as previously reported 12, 13 . We measured levels of the 40-amino-acid and 42-amino-acid amyloidb isoforms (Ab 40 and Ab 42 ) in conditioned media after 6-week differentiation. FAD ReN cells revealed dramatic increases in Ab 40 (,9-fold) and Ab 42 (,17-fold) levels as compared to the control ReN cells (Fig. 1b and Extended Data Fig. 2i ). The Ab 42 :Ab 40 ratio was also increased (,5-fold) in ReN cells expressing PSEN1(DE9) (Fig. 1b) . Treatment with bor c-secretase inhibitors markedly decreased amyloid-b levels ( Fig. 1c) with no appreciable toxicity (data not shown). We confirmed that ReN cells carry the APOE e3/e3 genotype, not the e4 allele associated with Alzheimer's disease (Extended Data Fig. 2j ).
In conventional 2D cultures, secreted amyloid-b diffuses into a large volume of media. We hypothesized that a 3D culture would accelerate amyloid-b deposition by limiting diffusion of amyloid-b, allowing for aggregation [15] [16] [17] . We chose BD Matrigel (BD Biosciences) as a 3D support matrix since it contains high levels of brain extracellular matrix proteins. For immunofluorescence and biochemical analyses, we set up thin-(,100-300 mm) and thick-layer (,4 mm) 3D culture models (Figs 2a  and 3a 
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2-6 weeks of differentiation (Supplementary Videos 1, 2 and 3). To demonstrate ReN-cell differentiation in thick-layer 3D cultures, paraffinsectioned thick-layer 3D cultures were analysed by immunofluorescence with various neuronal markers (Extended Data Fig. 3 ). qPCR array data indicated that 3D cultures promote more neuronal and glial differentiation than 2D cultures (Extended Data Fig. 2c ). We also observed a dramatic increase in the levels of 4-repeat adult tau isoforms in 3D cultures versus 2D (Extended Data Fig. 2d ). These data demonstrate that 3D culture conditions not only promote neuronal maturation, but also increase adult tau isoform levels, which are essential for reconstituting tauopathy 18 . To detect amyloid-b deposits, 3D-differentiated ReN cells were stained with the anti-amyloid-b antibody 3D6 (Fig. 2b) . Notably, confocal microscopy showed robust increases in extracellular amyloid-b deposits in FAD ReN cells (Fig. 2b) . Confocal Z-sectioning exhibited 3D extracellular amyloid-b aggregates with diameters of 10-50 mm ( Fig. 2c and Supplementary Video 4). Immunohistochemistry (IHC) with the BA27 anti-Ab 40 antibody reconfirmed robust increases in amyloid-b aggregates and diffuse amyloid-b staining in FAD ReN cells ( Fig. 2d and Extended Data Fig. 4a-c) . Treatment with b-or c-secretase inhibitors dramatically decreased amyloid-b deposits ( Fig. 2d and Extended Data Fig. 4a ). Accumulation of insoluble amyloid-b aggregates was also confirmed by Amylo-Glo, a fluorescent amyloid-specific dye (Biosensis; Fig. 2e and Extended Data Fig. 4d) Fig. 2d and Extended Data Fig. 4a ). For biochemical analysis, 3D-differentiated ReN cells were homogenized in Tris-buffered saline (TBS) and underwent a serial extraction protocol with 2% sodium dodecyl sulphate (SDS) and formic acid (Fig. 3a-c) . Western blot analysis with the anti-amyloid-b antibody 6E10 revealed increased amyloid-b levels in SDS-soluble fractions of FAD ReN cells (Fig. 3b) . In addition to a ,4-kDa amyloid-b monomer band, we observed amyloid-b dimer, trimer and tetramer bands in FAD ReN cells with high Ab 42 levels (Fig. 3b) . Amyloid-b dimers were detected in formic-acid-soluble fractions, especially in HReN-mGAP cells, which generated the highest levels of Ab 40 and Ab 42 (Fig. 3b) .
In Alzheimer's disease, tau protein is hyperphosphorylated and abnormally accumulates in axons, dendrites and cell bodies 20 . To analyse phosphorylated tau (p-tau) levels in FAD ReN cells, we performed western blot analysis with antibodies against p-tau (phosphorylated at Ser 199/Ser 202/Thr 205, AT8), and showed that p-tau levels were strongly increased in SDS-soluble fractions (Fig. 3c) . Species of p-tau were also detected in formic-acid-soluble fractions in HReN-mGAP cells, which showed the highest accumulation of insoluble amyloid-b (Fig. 3b, c) . Moderate increases of total tau levels were detected in FAD ReN cells, particularly in HReN-mGAP cells (Fig. 3c) , which might be explained by robust increases in aggregated tau fractions. Notably, the c-secretase inhibitor DAPT not only blocked amyloid-b generation but also inhibited p-tau levels in HReN-mGAP cells (Extended Data Fig. 5a, b) . For further exploration of p-tau accumulation at the cellular level, we performed IHC staining with two different p-tau antibodies, AT8 and PHF1 (p-tau phosphorylated at Ser 396/Ser 404). We found dramatic increases in p-tau levels in a small portion of FAD ReN cells (Extended Data Fig. 5c-g ). These cells displayed unusual morphologies, including beaded processes that are similar to the dystrophic neurites found in the brains of Alzheimer's disease patients (Extended Data Fig. 5c-e) . Additionally, areas with highly dense p-tau-positive processes could only be detected in FAD ReN cells (Extended Data Fig. 5e, f) . Treatment with either b-or c-secretase inhibitors decreased p-taupositive cell numbers in FAD ReN-mAP cells (Extended Data Fig. 5h ). These data strongly suggest that p-tau accumulations in FAD ReN cells are induced by amyloid-b accumulation.
To enhance amyloid-b and p-tau pathologies, ReN-mAP cells with the top 1-2% mCherry signals were enriched by FACS (Extended Data  Fig. 6a, b) . Inhibitors of b-or c-secretase decreased Ab 40 and Ab 42 levels in these cells while the c-secretase modulator SGSM41 preferentially decreased toxic Ab 42 levels and increased Ab 38 levels (Extended Data Fig. 6c ) 19 . PHF1 p-tau levels were also dramatically elevated in the enriched ReN-mAP cells (Fig. 4a, b) . PHF1/MAP2 (anti-p-tau/antimicrotubule associated protein 2) and AT8/Tuj1(anti-p-tau/anti-btubulin type III) co-immunofluorescence analysis showed that p-tau levels were largely increased in neurites and neuronal cell bodies ( Fig. 4a and Extended Data Fig. 7a ). IHC analysis confirmed the dramatic increases in PHF1 p-tau levels in the enriched ReN-mAP cells (Fig. 4b) . Notably, treatment with b-or c-secretase inhibitors reduced the elevated p-tau levels, especially in neurite-like structures (Fig. 4b) . Western blot analysis also showed that p-tau levels were robustly increased 
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in the enriched ReN-mAP cells while total tau levels were unchanged (Extended Data Fig. 7b ). A b-secretase inhibitor again decreased p-tau levels without affecting total tau levels (Extended Data Fig. 7b ). We further explored whether elevated p-tau proteins are aggregated in a manner similar to those observed in the degenerating neurons of Alzheimer's disease. Levels of p-tau were markedly increased in sarkosylinsoluble fractions of the enriched ReN-mAP cells, but not in control ReN-m cells (Fig. 4c) 
21
. The high-molecular-mass p-tau bands were detected only in sarkosyl-insoluble fractions of the enriched ReN-mAP cells, suggesting the presence of sarkosyl/SDS-resistant tau aggregates (Fig. 4c) . Next, we performed modified Gallyas silver staining 22 on cells that had undergone 10 weeks of differentiation. Notably, strong silver depositions in cell bodies and neurite-like structures were detected in the enriched ReN-mAP, but not in the enriched ReN-m control cells (Fig. 4d, arrows) . Finally, immunoelectron microscopy was employed to search for filamentous assemblies of tau protein in sarkosyl-insoluble fractions. Sarkosyl-insoluble fractions from 7-week differentiated ReNmAP (enriched) and control ReN-G cells were analysed using transmission electron microscopy. Filamentous structures labelled with an anti-tau (tau 46 ) antibody were detected in ReN-mAP cells, not in ReN-G cells ( Fig. 4e and Extended Data Fig. 8a, b) . The resulting p-tau aggregates shared striking similarity with those observed in the brains of Alzheimer's disease patients 20 . We also found that the GSK3b inhi- . While increased p-tau levels have been reported in several Alzheimer's disease mouse models with FAD mutations, no somatic accumulated aggregates, detergent-resistant/silver-positive p-tau aggregates, nor immunogold-labelled detergent-resistant tau fibrils were observed 4, 5 . The discrepancies between mouse FAD models and our 3D culture model might be a result of high levels of amyloid-b toxicity that can only be achieved in in vitro 3D culture conditions, or the differential tau gene structures in humans. We have shown that 3D-differentiated ReN cells exhibited a dramatic increase in mature human 4-repeat tau isoforms, which may be important for reconstituting tauopathy (Extended Data  Fig. 2d ). Indeed, a recent study showed that a rat FAD model, which has six tau isoforms similar to human, displayed some aspects of tauopathy 27 . Moreover, all aspects of tauopathy in our FAD hNPC models were 
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dramatically attenuated by b-or c-secretase inhibitors, most probably through the inhibition of amyloid-b generation. These data support that tauopathy is driven by the excessive accumulation of amyloid-b engendered by FAD mutations in our model.
In summary, we have successfully recapitulated amyloid-b and tau pathologies in a 3D human neural cell culture system, which can be used as a platform for studying the pathogenic mechanisms of Alzheimer's disease and drug screening. Our 3D neural cell culture model also provides a unique platform to explore the molecular mechanisms by which p-tau pathologies are induced by toxic amyloid-b species in the absence of frontotemporal lobar degenerative tau mutations. Most importantly, we provide experimental validation of the amyloid hypothesis of Alzheimer's disease, which proposes that the accumulation of amyloid-b drives tauopathy. Our unique strategy for recapitulating Alzheimer's disease pathology in the 3D human neural cell culture model may also serve to facilitate the development of more precise human cellular models of other neurodegenerative disorders.
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Published online 12 October 2014. in a CO 2 cell culture incubator. The cell culture media were changed every 3 days until the cells were confluent. For 2D neuronal/glial differentiation, the cells were plated onto either Matrigel-coated 24-well or 6-well plates with DMEM/F12 differentiation media supplemented with 2 mg ml 21 heparin, 2% (v/v) B27 neural supplement, and 1% (v/v) penicillin/streptomycin/amphotericin-b solution without growth factors. One half volume of the differentiation media was changed every 3 days for 3-7 weeks. DAPT, compound E and b-secretase inhibitor IV were purchased from EMD Millipore; N-lauroylsarcosine (Sarkosyl) from Sigma-Aldrich; haematoxylin QS from Vector Laboratories (Burlingame, CA, USA); and AmyloGlo from Biosensis (Thebarton, Australia). SGSM41 is an aminothiazole-bridged heterocycle-containing soluble c-secretase modulator (SGSM) similar in structure to those published recently 19 . SGSM41 has the typical characteristics of this series of SGSM molecules that potently inhibit the production of Ab 42 and to a lesser degree Ab 40 , while concomitantly increasing the generation of shorter amyloid-b peptide species such as Ab 38 and Ab 37 . The structure and the detailed properties are included in Extended Data Table 1 . Complementary DNA constructs and viral packaging. The construct encoding full-length human b-amyloid precursor protein (APP 695 ) with the V717I (London) mutation was obtained from O. Berezovska (Massachusetts General Hospital, Boston, MA, USA; GenBank accession no. NM_201414). The human presenilin 1 (PSEN1) construct with DE9 mutation was a gift from J. Hardy (NIH, Bethesda, MD, USA; GenBank accession no. NM_000021). To introduce K670N/M671L (Swedish) mutations into the APP 695 (London) gene, we performed a site-directed mutagenesis using a mutagenic primer set, 59-CGGAGGAGATCTCTGAAGTGAATTTGGA TGCAGAATTCCGA-39 and 59-TCGGAATTCTGCATCCAAATTCACTTCAG AGATCTCCTCC G-39 by using the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). APP (Swedish/London) and/or PSEN1(DE9) cDNAs were then PCR-amplified with Pfu (New England Biolabs, Ipswich, MA, USA) and cloned into lentiviral polycistronic CSCW-IRES-GFP or CSCW-IRES-mCherry vectors to generate CSCW-APP-GFP, CSCW-PSEN1(DE9)-mCherry and CSCW-APP-IRES-PSEN1(DE9)-IRES-mCherry. The parental CSCWIGs vector was provided by Massachusetts General Hospital (MGH) viral core. The primers used for the cloning were: APP, 59-CACCGCTAGCCAGGGTCGCGA ATGCTGC-39 and 59-GGCGTCGACCTAGTTCTGCATCTGCTC-39; PSEN1, 59-CACCGCTAGCAGTTGCTCCAATGACAGAGTTAC-39 and 59-GACCTCGAG CTAGATATAAAATTGATGGAATGC-39. The amplified APP or PSEN1 genes were double-digested with NheI/SalI or NheI/XhoI and ligated to either CSCW-IRES-GFP or CSCW-IRES-mCherry vectors. To make CSCW-APP-IRES-PSEN1(DE9)-IRES-mCherry vector, the APP-IRES segment of CSCW-APP-IRES-GFP vector was PCR-amplified with 59-CACCGCTAGCCAGGGTCGCGAATGCTGC-39 and 59-GGCGCTAGCGGTTGTGGCCATATTATCATC-39 primers, digested with NheI and cloned into the NheI site of CSCW-PSEN1(DE9)-mCherry vector. All the newly constructed vectors were confirmed by sequencing (MGH sequence core. Charlestown, MA, USA). Viral packaging and titre determination were performed by MGH viral core (Charlestown, MA, USA). Viral infection of ReN cell VM. To transfect the ReN cells with the lentiviral constructs, 50-100 ml viral solution (1 3 10 6 TU ml
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) were added to 85% confluent proliferating ReN cells in 6-well dishes, incubated for 24 h, and washed three times to stop the infection. The expression of the infected genes was confirmed by mCherry or GFP expression by fluorescence microscopy and western blot analysis. FACS enrichment of the transfected ReN cells. The infected ReN cells were washed with PBS and then incubated with Accutase (Millipore) for 5 min. The cell pellets were resuspended in PBS supplemented with 2% serum replacement solution (Life Technologies) and 2% B27, and then passed through a cell strainer filter (70 mm Nylon, BD Biosciences). The cell concentrations were adjusted to 2 3 10 6 cells per ml and then enriched by using FACSAria cell sorter (Broad Institute of MIT and Harvard, Cambridge, MA, USA). GFP and/or mCherry channels were used to detect the expression of the transfected genes in the individual cells. The sorted/ enriched cells were maintained in normal proliferation media. Amyloid-b ELISA. Ab 40 and Ab 42 levels were mainly measured by Human/Rat amyloid-b ELISA Kit from Wako (Osaka, Japan). The conditioned media from undifferentiated or differentiated ReN cells were collected and diluted by 1:10 or 1:100 with a dilution buffer provided by the manufacturer. A Synergy 2 ELISA plate reader (BioTek, Winooski, VT, USA) was used to quantify Ab 40 and Ab 42 ELISA signals. To simultaneously measure Ab 38 , Ab 40 and Ab 42 levels, a multi-array electrochemiluminescence ELISA kit was used (Meso Scale Discovery, Rockville, MD, USA). APOE genotyping. Genomic DNA (5 ng) isolated from undifferentiated ReN-m and ReN-mAP cells was PCR amplified using TaqMan probes for the two APOE SNP markers (rs429358, catalogue no. C_3084793_20 and rs7412, catalogue no. C_904973_10) using TaqMan Universal Master Mix II (Life Technologies). DNA samples of known APOE e4 genotypes (in duplicate) were used as controls to obtain the genotype clusters, and all the samples were PCR amplified on a CFX384 thermal cycler (Bio-Rad, Hercules CA, USA). 3D cell cultures and differentiation. For thin-layer 3D cultures, BD Matrigel stock solution (BD Biosciences) was diluted with ice-cold ReN cell differentiation medium (1:15 dilution ratio) and then vortexed with the cell pellets for 20 s. The final cell concentration for the mixture was approximately 2 3 10 6 cells per ml. The cell/ Matrigel mixtures were immediately transferred into either Optilux Black/Clear bottom 96-well plates (100 ml in each well, BD Biosciences) or 8-chamber well LabTek II coverglass plates (200 ml in each well, Thermo Scientific, Rockford, IL, USA) using pre-chilled pipettes. The plates were incubated for 1 h at 37 uC to form thinlayer (100-300 mm) 3D gels at the bottom of the plates and the media were changed. The 3D-plated cells were differentiated for 4-12 weeks depending on the experiments; media was changed every 3-4 days. For thick-layer 3D cultures, BD Matrigel solution was diluted with the same volume of the ice-cold ReN cell differentiation medium (1:2 dilution ratio) and vortexed with ReN cell pellets for 20 s. The final cell concentration for the mixture was approximately 1 3 10 7 cells per ml. Fourhundred microlitres of the cell/Matrigel mixtures were immediately transferred into tissue culture inserts (ThinCerts, 0.4 mm pore size, Greiner Bio-One, Monroe, NC, USA) and then placed in 24-well plates (BD Biosciences). After 1 h incubation at 37 uC, 1 ml of the pre-warmed differentiation media was added and the cultures were maintained for 4-12 weeks; media was changed every 3-4 days. For drug treatments, differentiation media containing either 1 mM b-secretase inhibitor IV, 1 mM DAPT, 3.7 nM compound E or the same volumes of DMSO were added to 4-6-week differentiated 3D-cultured ReN cells and then maintained for an additional 2-3 weeks. The cells were either fixed with 4% paraformaldehyde (PFA) or harvested for extraction and western blot analysis. Paraffin embedding and sectioning of thick-layer 3D cultures. For paraffin embedding, 3D thick layer cultures were fixed with 4% PFA at room temperature overnight. The PFA-fixed Matrigel was then transferred to a plastic Tissue-Tek Cryomold (Sakura Finetek, Torrance, CA, USA), preloaded with 60 uC liquefied HistoGel (Thermo Scientific). After positioning the fixed 3D Matrigel at the centre, the whole Cryomold with Histogel/Matrigel was transferred on ice and then incubated for 15 min until the Histogel was solidified. The Histogel/Matrigel complex was then further fixed with 4% PFA at 4 uC overnight, washed five times with PBS, and sent for paraffin embedding (MGH pathology core, Charlestown, MA, USA). The paraffin blocks were then cut into 10 mm sections (Leica SM2010R sliding microtome, Leica Microsystems Inc., Buffalo Grove, IL, USA), mounted on polylysine-coated glass slides (Thermo Scientific), and incubated at 45 uC overnight. The sections were deparaffinized by two changes of xylene for 5 min each and then serially transferred to 100%, 90%, 70% ethanol solution for 1 min each. The sections were then rinsed with distilled water for 5 min. For immunofluorescence and IHC, the antigen retrieval was performed by heating the slides for 30 min in Citrate-EDTA Buffer containing 10 mM citric acid (pH 6.2), 2 mM EDTA and 0.05% Tween-20. Immunofluorescence staining. For immunofluorescence of 3D-cultured ReN cells, thin-layer 3D cultures were fixed with 4% PFA at room temperature for 24 h. The fixed cells were then permeabilized and blocked by incubating with a blocking solution containing 50 mM Tris (pH 7.4), 0.1% Tween-20, 4% donkey serum, 1% BSA, 0.1% gelatin and 0.3 M glycine at 4 uC for 12 h. After washing with TBS buffer containing 0.1% (v/v) Tween-20 (TBST), the 3D cultures were incubated with primary antibodies in the blocking solution at 4 uC for 24 h. After washing three times with TBST, the cells were then incubated with TBST overnight with gentle rocking at 4 uC and then further incubated with AlexaFluor secondary antibodies (Life Technologies) overnight at 4 uC. To avoid fluorescence quenching, a drop of anti-fade gold (Life Technologies) was added on top of the fixed/stained thin-layer 3D cultures before imaging. The fluorescence images were captured by an Olympus DSU confocal microscope (Olympus USA, Center Valley, PA, USA) and the image analysis and 3D reconstitution were performed with ImageJ (a public domain image analysis software), IPlabs (BioVision Technologies, Exton, PA, USA) and MetaMorph (Molecular Devices, Sunnyvale, CA, USA) software. The following antibody dilution rates were used in this study: 3D6 anti-amyloid-b antibody (1:500, a gift from Immunohistochemical staining. For IHC, thin-layer 3D cultures were permeabilized and blocked by incubating with the blocking solution at 4 uC for 12 h. To block endogenous peroxidase activities, the cultures were incubated with 0.05% (v/v) H 2 O 2 solution in TBS for 5 min at room temperature, washed with TBST three times and incubated with the blocking solution for 2 h at room temperature. After incubating with the primary antibody solutions for 24 h at 4 uC, the cultures were washed five times with TBST and then incubated with ImmPRESS anti-mouse or -rabbit Ig (ImmPRESS Peroxidase Polymer Detection Kit, Vector Laboratories, Burlingame, CA, USA) for 30-60 min. The cultures were washed five times for 10 min each with TBST and developed by using ImmPACT DAB Peroxidase Substrate kit (Vector Laboratories). The following antibodies and dilution rates have been used in this study: BA27 anti-Ab 40 antibody horseradish peroxidase (HRP)-conjugate (1:2, Wako Chemicals USA, Richmond, VA, USA); BC05 anti-Ab 42 antibody HRP-conjugate (1:2, Wako Chemicals USA); AT8 anti-p-tau antibody (1:40, Thermo Scientific); PHF1 anti-p-tau antibody (1:1,000), anti-MAP2 antibody (1:200, Cell Signaling Technology); ImmPRESS anti-mouse and -rabbit Ig HRP polymer conjugates (1:2, Vector Laboratories). Differential detergent extraction for western blot. The thick-layer 3D cultures of ReN cells were homogenized with TBS extraction buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM NaVO 3 , 1 mM NaF, a protease inhibitor mixture (Roche Molecular Biochemicals), a phosphatase inhibitor cocktail (Thermo Scientific), 2 mM PNT (EMD Millipore) and 1 mM phenylmethylsulphonyl fluoride (PMSF, Sigma-Aldrich) by using a battery-operated spinning homogenizer (MIDSCI, St Louis, MO, USA). After incubation on ice for 10 min, the samples were centrifuged for 1 h at 100,000g to get TBS-soluble fractions. The TBS-insoluble pellets were then resuspended in 2% SDS extraction buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 2% SDS, 1% Triton X-100, 1 mM NaVO 3 , 1 mM NaF, a protease inhibitor mixture (Roche Molecular Biochemicals), a phosphatase inhibitor cocktail (Thermo Scientific), 2 mM PNT (EMD Millipore) and 1 mM PMSF (Sigma-Aldrich) and incubated on ice for an additional 30 min. The samples were centrifuged for 1 h at 100,000g and the supernatant fractions were collected as TBS-insoluble/2% SDSsoluble fractions. The 2% SDS-insoluble pellets were briefly washed with SDS extraction buffer and then further extracted with 90% formic acid (Sigma-Aldrich) on ice and centrifuged for 1 h at 100,000g to produce TBS-insoluble/2% SDSinsoluble/formic-acid-soluble fractions. The formic acid fractions were enriched by using SpeedVac and neutralized by 2 M Tris-Cl buffer (pH 8.3). Protein levels of SDSsoluble fractions were used to normalize the total protein levels in TBS and formic acid fractions. Purification of sarkosyl-insoluble tau was performed as previously described 28,29 with modifications. TBS-insoluble pellets were resuspended in 1% sarkosyl/RIPA buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 0.5% w/v sodium deoxycholate, 2% v/v NP-40, 1% w/v N-lauroylsarcosine, a protease inhibitor mixture (Roche Molecular Biochemicals), a phosphatase inhibitor cocktail (Thermo Scientific), 1 mM NaF, 1 mM NaVO 3 , 2 mM PNT (EMD Millipore) and 1 mM PMSF (Sigma-Aldrich) and incubated on ice for 1 h. The samples were then centrifuged for 1 h at 100,000g and the supernatant fractions were collected as 1% sarkosyl/RIPA-soluble fractions. The insoluble pellets were briefly washed two times with 1% sarkosyl/RIPA buffer, further extracted with 90% formic acid (SigmaAldrich) on ice and centrifuged for 1 h at 100,000g to produce 1% sarkosyl/RIPAinsoluble /formic-acid-soluble fractions. Western blot analysis. 15-75 mg of protein were resolved on 12% Bis-Tris or 4-12% gradient Bis/Tris gels (Life Technologies) and the proteins were transferred to nylon membranes (Bio-Rad). For amyloid-b western blot analysis, the membranes were crosslinked with 0.5% glutaraldehyde solution before blocking. Western blot images were visualized by enhanced chemiluminescence (ECL). The images were captured by using BioMax film (Kodak, Rochester, NY, USA) or a VersaDoc imaging system (Bio-Rad) and quantitated by using QuantityOne software (Bio-Rad). Primary antibodies were used at the following dilutions: 6E10 anti-amyloid-b (1:300, Convance); anti-PSEN1 (1:1,000, Cell Signaling Technology); anti-a-tubulin (1:1,000, Cell Signaling Technology); anti-CNPase (1:1,000, Cell Signaling Technology); antib-secretase 1 (1:1,000, Cell Signaling Technology); C66 APP C-terminal antibody (1:2,000); AT8 anti-p-tau (1:100, Millipore); PHF1 anti-p-tau (1:500); anti-total tau (1:2,000, DAKO); anti-MAP2 (1:500, Millipore; 1:200, Cell Signaling); anti-NCAM (1:1,000, Cell Signaling); anti-synapsin I (1:500, Cell Signaling); anti-HSP70 (1:1,000, Enzo Life Sciences, Farmingdale, NY, USA) and anti-human mitochondrial antigen (1:500, Millipore). Modified Gallyas silver staining. Gallyas silver staining was performed with a modified protocol described by Nadler et al.
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. The PFA-fixed thin-layer 3D cultures were washed three times with deionized distilled water (DDW) for 5 min and then incubated two times with a pretreating solution containing 4.5% (w/v) NaOH and 0.6% (w/v) ammonium nitrate. The cultures were then incubated with an impregnation solution containing 5.4% (w/v) NaOH, 6.4% (w/v) ammonium nitrate and 0.3% (w/v) silver nitrate for 10 min followed by three washes with a washing solution containing 1 ml of 0.0012% (w/v) ammonium nitrate, 0.5% (w/v) sodium carbonate and 28.5% (v/v) ethanol at 5-min intervals. The deposition of silver particles was detected by incubating with a developer solution with 0.012% (w/v) ammonium nitrate, 0.05% (w/v) citric acid, 0.56% (w/v) formalin and 9.5% (v/v) ethanol for 1-5 min. The reaction was stopped by adding 0.5% acetic acid. Amylo-Glo staining. The fixed 3D thin-layer cultures of ReN cells were washed three times with saline and incubated with 0.001% (v/v) Amylo-Glo solution for 5 min in a dark environment. The cells were then washed with saline followed by three washings with DDW. To avoid fluorescence quenching, a drop of anti-fade gold (Life Technologies) was added on top of the stained cells. The Amylo-Glo fluorescence was measured with an Olympus DSU confocal microscope with Metamorph image analysis software (Olympus). Congo red staining. Bennhold's Congo red staining protocol was used for staining paraffin sectioned 3D cultures with slight modification. The hydrated paraffinsectioned 3D cultures were incubated with 1% Congo red solution (Sigma-Aldrich) for 60 min at room temperature. After briefly rinsing with distilled water three times, the sections were dipped several times into an alkaline alcohol solution (30% EtOH, 0.01% (w/v) NaOH) until the background was cleared. The slides were then washed twice with DDW. RNA extraction, cDNA synthesis and quantitative RT-PCR (qPCR) analysis. Total RNAs were prepared by using RNeasy mini-columns (Qiagen, Valencia, CA, USA) according to the manufacturer's protocols. Complementary DNAs were synthesized by SuperScript III first-strand synthesis kit (Life Technologies). The prevalidated primer sets for neural markers were purchased from Real Time Primers, LLC (Elkins Park, PA, USA). The amplification was done in a final volume of 20 ml under the following conditions: 15 min at 95 uC and then 55 cycles at 95 uC for 10 s, 58 uC for 45 s and 72 uC for 45 s. The sizes of the qPCR products were confirmed by agarose gel electrophoresis. Biorad iCycler was used to determine count values for each sample. Gene expression levels were normalized against b-actin levels in each sample and the fold changes were calculated by setting the expression levels of each gene in undifferentiated control ReN-G cells as 1. The following are the neuronal and glial marker gene names and PCR product sizes: NCAM1 (neural cell adhesion molecule 1, 174 base pairs (bp)); SYT5 (synaptotagmin V, 171 bp); SLC17A7 (also known as VGLUT1, solute carrier family 17 (sodium-dependent inorganic phosphate co-transporter) member 7, 162 bp); GRIN2A (glutamate receptor, ionotropic, N-methyl D-aspartate 2A, 170 bp); EAAT3 (solute carrier family 1, member 1 (neuronal glutamate transporter), 165 bp); ACHE (acetylcholinesterase, 232 bp); SLC6A4 (solute carrier family 6 member 4 (neurotransmitter transporter, dopamine), 213 bp); GABRA1 (c-aminobutyric acid (GABA) A receptor alpha 1, 165 bp); MAPT (microtubule-associated protein tau, 206 bp); S100b (S100 calcium binding protein, 157 bp); GFAP (glial fibrillary acidic protein, 183 bp); EAAT2 (solute carrier family 1, member 2 (EAAT2, glial), 158 bp); MBP (myelin basic protein, 183 bp); and ACTB (b-actin, 233 bp).
RT-PCR analysis of 3-repeat and 4-repeat tau levels. Relative levels of 3-repeat and 4-repeat tau mRNAs were determined by RT-PCR using the primer sets: forward 59-AAGTCGCCGTCTTCCGCCAAG-39; reverse 59-GTCCAGGGACCCA ATCTTCGA-39 as previously described 30 . The PCR amplification was performed in a final volume of 20 ml under the following conditions: 95 uC for 15 min, and then 30 cycles at 94 uC for 30 s, 60 uC for 30 s and 74 uC for 90 s with a final 10 min extension at 74 uC. RT-PCR products were analysed on 2% agarose gel: 4-repeat tau, 381 bp; 3-repeat tau, 288 bp. Preparation of sarkosyl-insoluble tau fibrils for immunoelectron microscopy. Sarkosyl-insoluble tau fibrils were prepared from FAD-ReN (ReN-mAP (enriched)) cells, which were differentiated in 3D for 7 weeks 28, 29 . 3D-cultured cell pellets were homogenized in one volume of TBS extraction buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM NaVO 3 , 1 mM NaF, a protease inhibitor mixture (Roche Molecular Biochemicals), a phosphatase inhibitor cocktail (Thermo Scientific), 2 mM PNT (EMD Millipore) and 1 mM PMSF (Sigma-Aldrich) by using a battery-operated spinning homogenizer (MIDSCI). TBS homogenates were then mixed and homogenized with one volume of 23 RIPA buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 0.5% w/v sodium deoxycholate, 2% v/v NP-40, a protease inhibitor mixture (Roche Molecular Biochemicals), a phosphatase inhibitor cocktail (Thermo Scientific), 1 mM NaF, 1 mM NaVO 3 , 2 mM PNT (EMD Millipore) and 1 mM PMSF (Sigma-Aldrich), and incubated on ice for 15 min. After centrifugation (18,000g for 20 min at 4 uC), 20% w/v N-lauroylsarcosine (sarkosyl) stock solution was added to the RIPA-soluble supernatant fraction to adjust the final sarkosyl concentration to 1%. After incubating at room temperature with gentle rocking for 1 h, RIPA/ sarkosyl homogenates were then centrifuged for 1 h at 150,000g. The pellets were then resuspended in 10 ml of PBS (RIPA-soluble/sarkosyl-insoluble fraction). The
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RIPA-insoluble pellets were further homogenized in H buffer containing 10 mM Tris (pH 7.4), 1 mM EGTA, 0.8 M NaCl, 10% w/v sucrose, a protease inhibitor mixture (Roche Molecular Biochemicals), a phosphatase inhibitor cocktail (Thermo Scientific), 1 mM NaF, 1 mM NaVO 3 , 2 mM PNT (EMD Millipore) and 1 mM PMSF (Sigma-Aldrich) and then centrifuged at 18,000g for 20 min. 20% w/v Nlauroylsarcosine (sarkosyl) stock solution was added to adjust the final sarkosyl solution concentration to 1%. After incubating at room temperature with gentle rocking for 1 h, H buffer/sarkosyl homogenates were then centrifuged for 1 h at 150,000g and the pellets were resuspended in 10 ml of PBS (RIPA-insoluble/sarkosyl-insoluble fraction). Both RIPA-soluble/sarkosyl-insoluble and RIPA-insoluble/sarkosyl-insoluble fractions were used for immunoelectron microscopy. The same protocol was used to enrich sarkosyl-insoluble p-tau aggregates in Alzheimer's disease brain samples.
Immunogold staining of sarkosyl-insoluble tau. Immunoelectron microscopy was performed in the Microscopy Core of the Center for Systems Biology/Program in Membrane Biology (MGH, Boston, USA). The sarkosyl-insoluble fractions were resuspended in PBS, placed on formvar-carbon coated Ni grids and allowed to adsorb for 10 min. They were placed on drops of tau 46 antibody solution (1:25, Cell Signaling Technology) for 1 h at room temperature, then rinsed on drops of PBS and placed on drops of goat-anti-mouse 10 nm gold (Ted Pella, Redding, CA, USA) for 1 h. They were rinsed on drops of distilled water and stained for 1 min on drops of 2% phosphotungstic acid (Electron Microscopy Sciences, Hatfield, PA, USA). Grids were examined in a JEOL JEM 1011 transmission electron microscope at 80 kV.
Images were collected using an AMT digital imaging system (Advanced Microscopy Techniques, Danvers, MA, USA). Electrophysiology. Whole-cell recordings were performed on differentiated ReN cells with an Axopatch 200A amplifier (Molecular Devices) and fire polished patch pipettes with resistances of 2-3 MV. Pipette solution was 140 mM KCl, 2 mM MgCl 2 , 1 mM EGTA, 10 mM HEPES, 4 mM MgATP, 0.3 mM NaGTP, and 0.1 mM Na 2 PhosCr, pH 7.2, adjusted with KOH. The external solution was 140 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES, and 10 mM D-glucose, pH 7.4, adjusted with NaOH. Command protocols were generated and data were digitized with a Digidata 1440A A/D interface with pCLAMP10 software (Molecular Devices). Voltage errors were minimized by series resistance compensation (80%). During the recording, 500 nM tetrodotoxin was applied to isolate Na 1 currents by subtracting currents after and before tetrodotoxin application. The data were analysed by Clampfit (Molecular Devices) and Sigmaplot. Statistics. All statistical analyses were performed using a two-tailed Student's t-test or one-way ANOVA followed by a post hoc Dunnett's test. Data in graphs are expressed as mean values 6 s.e.m. Error bars represent s.e.m. LETTER RESEARCH
